MedPath

Amplimed Corporation

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:0
Completed:6

Trial Phases

2 Phases

Phase 1:5
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)โ€ข Click on a phase to view related trials

Phase 1
5 (71.4%)
Phase 2
2 (28.6%)

A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

Phase 2
Withdrawn
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2008-06-13
Last Posted Date
2015-06-24
Lead Sponsor
AmpliMed Corporation
Registration Number
NCT00697060
Locations
๐Ÿ‡บ๐Ÿ‡ธ

USC Norris Cotton Cancer Center, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mary Crowley Research Center, Dallas, Texas, United States

A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Neoplasms
Interventions
First Posted Date
2008-03-17
Last Posted Date
2019-03-20
Lead Sponsor
AmpliMed Corporation
Target Recruit Count
142
Registration Number
NCT00637247
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Birmingham Hematology and Oncology- US Oncology, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

AZ Onc Associates D.B.A. Hematology Oncology- US Oncology, Tucson, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Arizona Clinical Research Center, Tucson, Arizona, United States

and more 44 locations

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

Phase 1
Completed
Conditions
Pancreatic Adenocarcinoma
First Posted Date
2006-05-18
Last Posted Date
2010-09-15
Lead Sponsor
AmpliMed Corporation
Target Recruit Count
105
Registration Number
NCT00327327
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Arizona Clinical Research Center, Tucson, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

US Oncology Orlando, Cancer Centers of FL, Ocoee, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

US Oncology Indiana, Indianapolis, Indiana, United States

and more 6 locations

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Phase 1
Completed
Conditions
Malignant Melanoma
Interventions
First Posted Date
2006-05-18
Last Posted Date
2010-09-15
Lead Sponsor
AmpliMed Corporation
Target Recruit Count
68
Registration Number
NCT00327600
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Investigational Site 009, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Investigational Site 002, Santa Monica, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of CO Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 8 locations

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

Phase 1
Completed
Conditions
Multiple Myeloma
First Posted Date
2006-05-18
Last Posted Date
2009-08-11
Lead Sponsor
AmpliMed Corporation
Registration Number
NCT00327249
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Investigational Site 025, Little Rock, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Investigational Site 008, Houston, Texas, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.